文献速递慢性静脉疾病静脉血栓栓塞

病变形态指导的髂股静脉血栓后闭塞腔内治疗:单中心回顾性队列研究

Lesion Morphology-Guided Endovascular Treatment for Postthrombotic Iliofemoral Venous Obstruction: A Retrospective Single-Center Cohort Study.
PubMed 文献 · Ann Vasc Surg · 2026-07-29

本研究回顾性纳入342例血栓后髂股静脉闭塞(PIVO)患者,按病变形态分配单纯球囊扩张(PTA)、支架或联合药物机械性血栓清除(PMT)/导管接触性溶栓加支架治疗。36个月一期通畅率分别为51.3%、64.0%和57.0%(P=0.041),支架在长段和闭塞性病变中优于PTA,而短段非闭塞性狭窄伴良好流入道时单纯PTA通畅率无差异。

要点

  • 病变形态指导的治疗分配策略在PIVO中可获得可接受的中期通畅率。
  • 长段或闭塞性病变支架置入优于单纯PTA,短段非闭塞性狭窄伴良好流入道时两者无差异。
  • 流入道评分≥2、完全闭塞和病变长度≥10 cm是通畅率丢失的独立预测因素。

核心结论

  • 病变形态指导的治疗分配策略在PIVO中产生可接受的中期通畅率。
  • 支架置入对长段和闭塞性病变提供更优结局,而单纯PTA对经仔细选择的短段、非闭塞性狭窄伴保留流入道者可能合理。

研究设计与样本

  • 回顾性单中心队列研究,纳入2019年1月至2023年12月共342例确诊PIVO患者(距首次深静脉血栓≥3个月,Villalta评分≥5)。
  • 根据病变形态分配治疗:短段(<5 cm)非闭塞性病变伴良好流入道(流入道评分0)行单纯PTA;长段(≥5 cm)或闭塞性病变伴足够流入道行支架置入;复杂病变伴差流入道(流入道评分≥2)行联合PMT/导管接触性溶栓加支架。

主要发现

  • PTA、支架和联合手术的技术成功率分别为93.6%、96.3%和94.0%。
  • 36个月一期通畅率:PTA为51.3%(95%CI 40.2-62.4),支架为64.0%(95%CI 56.5-71.5),联合治疗为57.0%(95%CI 46.8-67.2)(log-rank P=0.041)。
  • 36个月二期通畅率分别为65.4%、80.5%和72.0%(P=0.018)。
  • 多变量Cox回归中,支架 vs PTA与通畅率丢失减少独立相关(HR 0.62,95%CI 0.43-0.89;P=0.009),流入道评分≥2(HR 1.92,95%CI 1.35-2.73;P<0.001)、完全闭塞(HR 1.63,95%CI 1.15-2.31;P=0.006)和病变长度≥10 cm(HR 1.56,95%CI 1.12-2.18;P=0.009)预测通畅率丢失。
  • 逆概率治疗加权后支架仍优于PTA(HR 0.58,95%CI 0.39-0.86;P=0.007);亚组分析显示支架获益集中于长段病变(≥5 cm;HR 0.42,交互作用P=0.003),短段非闭塞性病变通畅率无差异(HR 0.78,P=0.43)。

关键数值与推荐

  • 短段(<5 cm)非闭塞性病变伴流入道评分0可选择单纯PTA。
  • 长段(≥5 cm)或闭塞性病变伴足够流入道推荐支架置入。
  • 复杂病变伴流入道评分≥2推荐联合PMT/导管接触性溶栓加支架。

临床怎么用

  • 根据病变长度、闭塞状态和流入道评分进行个体化治疗分配,长段或闭塞性病变优先考虑支架置入。
  • 短段非闭塞性狭窄伴良好流入道可考虑单纯PTA以避免支架置入。
  • 对流入道评分≥2、完全闭塞或病变长度≥10 cm的高风险患者加强随访监测。

局限性

  • 回顾性单中心设计可能引入选择偏倚。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endovascular treatment of postthrombotic iliofemoral venous obstruction (PIVO) involves balloon angioplasty (percutaneous transluminal angioplasty [PTA]), stenting, or combined pharmacomechanical thrombectomy (PMT) with stenting, yet selection criteria remain poorly defined. This study evaluated outcomes of a lesion morphology-guided treatment allocation strategy. METHODS: In this retrospective, single-center cohort study (January 2019 to December 2023), 342 patients with confirmed PIVO (time since index deep vein thrombosis ≥3 months, Villalta score ≥5) treated at a tertiary vascular center were analyzed. Treatment was allocated based on lesion morphology: PTA alone for short-segment (<5 cm), nonocclusive lesions with good inflow (inflow score 0); stenting for long-segment (≥5 cm) or occlusive lesions with adequate inflow; and combined PMT/catheter-directed thrombolysis plus stenting for complex lesions with poor inflow (inflow score ≥2). The primary end point was 36-month primary patency. RESULTS: Technical success was achieved in 93.6%, 96.3%, and 94.0% of PTA, stenting, and combined procedures, respectively. At 36 months, primary patency was 51.3% (95% confidence interval [CI] 40.2-62.4) for PTA, 64.0% (95% CI 56.5-71.5) for stenting, and 57.0% (95% CI 46.8-67.2) for combined treatment (log-rank P = 0.041). The secondary patency was 65.4%, 80.5%, and 72.0%, respectively (P = 0.018). On multivariable Cox regression, stenting versus PTA was independently associated with reduced patency loss (hazard ratio [HR] 0.62, 95% CI 0.43-0.89; P = 0.009), while inflow score ≥ 2 (HR 1.92, 95% CI 1.35-2.73; P < 0.001), complete occlusion (HR 1.63, 95% CI 1.15-2.31; P = 0.006), and lesion length ≥10 cm (HR 1.56, 95% CI 1.12-2.18; P = 0.009) predicted patency loss. After inverse probability of treatment weighting, stenting remained superior to PTA (HR 0.58, 95% CI 0.39-0.86; P = 0.007). Subgroup analysis showed stenting benefit was concentrated in long-segment lesions (≥5 cm; HR 0.42, P-int [P-value for interaction] = 0.003); for short, nonocclusive lesions, patency did not differ (HR 0.78, P = 0.43). CONCLUSION: A lesion morphology-guided treatment allocation strategy yields acceptable mid-term patency in PIVO. Stenting provides superior outcomes for long-segment and occlusive lesions, while PTA alone may be reasonable for carefully selected short-segment, nonocclusive stenoses with preserved inflow.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Zhang X, Liu Y, Wang X, et al. Lesion Morphology-Guided Endovascular Treatment for Postthrombotic Iliofemoral Venous Obstruction: A Retrospective Single-Center Cohort Study. Ann Vasc Surg. 2026. PMID: 42526751. doi:10.1016/j.avsg.2026.07.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。